β2‐Adrenoreceptor Agonists, Montelukast, and Parkinson Disease Risk
Open Access
- 23 March 2023
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 93 (5), 1023-1028
- https://doi.org/10.1002/ana.26638
Abstract
ObjectiveThis study was undertaken to examine the association between montelukast use, beta 2-adrenoreceptor (beta 2AR) agonist use, and later Parkinson disease (PD). MethodsWe ascertained use of beta 2AR agonists (430,885 individuals) and montelukast (23,315 individuals) from July 1, 2005 to June 30, 2007, and followed 5,186,886 PD-free individuals from July 1, 2007 to December 31, 2013 for incident PD diagnosis. We estimated hazard ratios and 95% confidence intervals using Cox regressions. ResultsWe observed 16,383 PD cases during on average 6.1 years of follow-up. Overall, use of beta 2AR agonists and montelukast were not related to PD incidence. A 38% lower PD incidence was noted among high-dose montelukast users when restricted to PD registered as the primary diagnosis. InterpretationOverall, our data do not support inverse associations between beta 2AR agonists, montelukast, and PD. The prospect of lower PD incidence with high-dose montelukast exposure warrants further investigation, especially with adjustment for high-quality data on smoking. ANN NEUROL 2023Funding Information
- Knut och Alice Wallenbergs Stiftelse
- Parkinsonfonden
- Vetenskapsrådet (2013‐02488, 2017‐02175)
This publication has 23 references indexed in Scilit:
- Ethical aspects of registry-based research in the Nordic countriesClinical Epidemiology, 2015
- Risk of developing Parkinson's disease among patients with asthma: a nationwide longitudinal studyAllergy, 2015
- Clinical effectiveness and safety of montelukast in asthma. What are the conclusions from clinical trials and meta-analyses?Drug Design, Development and Therapy, 2014
- Accuracy and Sensitivity of Parkinsonian Disorder Diagnoses in Two Swedish National Health RegistersNeuroepidemiology, 2012
- Epidemiology and etiology of Parkinson’s disease: a review of the evidenceEuropean Journal of Epidemiology, 2011
- Montelukast and psychiatric disorders in childrenPharmacoepidemiology and Drug Safety, 2009
- Current Issues With β2-Adrenoceptor Agonists: Historical BackgroundClinical Reviews in Allergy & Immunology, 2006
- A meta‐analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's diseaseAnnals of Neurology, 2002
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987
- Partial residuals for the proportional hazards regression modelBiometrika, 1982